WATERTOWN, Mass. , June 17, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo ™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

In April 2022 , secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad

WATERTOWN, Mass. , May 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to control LYR-210 may improve mental and physical health and quality of life of CRS patients WATERTOWN,

WATERTOWN, Mass. , April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ENT) passages and other diseased

LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit of LYR-210 to Chronic Rhinosinusitis Patients WATERTOWN, Mass. , April 21, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc.

Private placement priced at-the-market under Nasdaq rules Proceeds to support Lyra's ongoing clinical development of LYR-210 and LYR-220 Proceeds, combined with existing cash and expected milestone payments, supports extension of cash runway into mid-2024 WATERTOWN, Mass.

WATERTOWN, Mass. , April 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting

Treated first patient in pivotal Phase 3 ENLIGHTEN program for surgically naïve chronic rhinosinusitis patients Initiated BEACON Phase 2 trial for LYR-220 in chronic rhinosinusitis patients with post-surgical anatomy Appointed Harlan W. Waksal, MD, as Executive Chairman WATERTOWN, Mass.